Tottenham Acquisition I Ltd. (NASDAQ:TOTA) announced in an 8-K filing that its shareholders approved its combination with biopharmaceutical firm Clene Nanomedicine Inc. at a special meeting earlier today.
The transaction was approved unanimously with 92.3% of shares participating, however Tottenham did not divulge redemption figures in the filing. The company went into the vote with an estimated $11.02 per share in trust and previously saw 58.6% of its shares redeemed through a series of extension votes. But, having opened ahead of the vote at $11.88, any further redemptions were likely limited.
Tottenham initially announced its $542 million combination with Clene Nanomedicine on September 2. Clene has developed a novel orally administered drug platform that could potentially treat multiple sclerosis, Parkinson’s disease, and ALS, with one Phase 3 trial and multiple Phase 2 clinical studies ongoing. It is also launching two additional Phase 2 COVID-19 studies with a second nanotherapeutic asset, CNM-ZnAg, in Brazil and Russia.
Several measures up for a vote at the meeting passed unanimously, however 131,903 shares voted against a number of proposed amendments to the combined company’s charter. For a full list of measures on the ballot as well as vote tallies, click HERE.
Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...
M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...
At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...
Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...
Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...